Patent ID: 9139644
Filing Date: 2015-09-22
Classification: A61K,A61P,C07H,C07K,C12N

Abstract:
1. A chimeric polypeptide capable of antagonizing VEGF activity consisting of a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component, wherein the modified extracellular ligand binding domain consists of an immunoglobulin-like (Ig) domain of human Flt1 and an Ig domain of human Flk1, wherein the Ig domain of human Flt1 is Ig domain 2, and wherein the Ig domain of human Flk1 is Ig domain 3, wherein the chimeric polypeptide exhibits improved pharmacokinetic properties as compared to a chimeric polypeptide consisting of only Ig domains of Flt1.